STOCK TITAN

ALLURION TECHNOLOGIES INC - ALUR STOCK NEWS

Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.

Overview of Allurion Technologies Inc

Allurion Technologies Inc is a specialized medical device company focused on providing a non-invasive weight loss platform that combines cutting-edge technology with a unique procedure-less approach. The company has engineered a revolutionary weight management system based on a swallowable intragastric balloon that is administered under the guidance of healthcare professionals without the need for surgery, endoscopy, or anesthesia.

Core Business and Value Proposition

The foundation of Allurion's offering is its proprietary intragastric balloon—a capsule that, once swallowed, provides a temporary space-occupying mechanism in the stomach to help patients achieve satiety and reduce overall caloric intake. This innovative device is seamlessly integrated with a digital care platform that includes AI-powered remote patient monitoring tools, secure messaging, and telehealth consultations. Such integration enables physicians to track patient progress, manage interventions remotely, and deliver personalized behavioral modification guidance. This dual-pronged approach not only enhances patient safety and convenience but also supports a sustained behavior change that is essential for long-term weight management.

Technology and Digital Integration

The Allurion Program represents a significant leap in the application of medical devices within the digital health sphere. By leveraging AI algorithms and sophisticated telehealth networks, the platform provides robust, real-time patient monitoring. This ensures that patients receive timely support and that any deviations in their weight loss journey are promptly addressed. The system encapsulates modern digital trends such as remote patient engagement, virtual consultations, and data-driven insights, positioning it at the forefront of technology-enabled healthcare solutions.

Operational Model and Market Position

Allurion Technologies operates within the competitive landscape of obesity management and medical weight loss solutions. Its business model centers on delivering a comprehensive, tech-enabled healthcare approach that integrates a one-time device usage with ongoing digital support services. This model allows the company to appeal to a wide range of patients who are seeking effective, non-surgical weight loss interventions. The procedure-less nature of the intragastric balloon reduces the risks and recovery time traditionally associated with invasive weight loss surgeries, making it an attractive option for healthcare providers and patients alike.

Industry Relevance and Competitive Advantages

Within the healthcare and medical device industry, Allurion is recognized for its innovative solution that addresses the prevalent need for safe and effective weight management techniques. Its unique blend of a physical device and a connected digital support system provides a comprehensive approach to weight loss that distinguishes it from both traditional bariatric procedures and emerging non-invasive alternatives. The company's commitment to integrating digital monitoring with clinical guidance builds trust among healthcare professionals and patients, underlining the effectiveness of its weight management methodology.

Benefits for Patients and Healthcare Providers

Patients benefit from an accessible, non-invasive treatment option that does not require the risks associated with surgery. The system's integrated remote monitoring not only promotes consistent patient engagement but also facilitates early detection of potential issues. Healthcare providers are supported by a streamlined process that includes secure patient communication, actionable health data, and the ability to provide tailored behavioral counseling. These features collectively enhance patient outcomes and support a rigorous clinical process that is both scalable and efficient.

Commitment to Quality and Safety

Allurion Technologies emphasizes rigorous clinical protocols and continuous improvements in device design and digital support mechanisms. The procedure-less approach reduces the barriers to treatment and provides a safer alternative to invasive surgeries. Through relentless innovation and adherence to stringent quality standards, the company maintains trust with both patients and healthcare providers, reinforcing its reputation as a reliable player in the field of non-invasive weight loss solutions.

Conclusion

Allurion Technologies Inc stands out as a comprehensive, technology-driven solution provider in the obesity management space. With its innovative swallowed intragastric balloon and integrated digital health platform, the company offers a distinctive, non-invasive alternative to traditional weight loss treatments. Its emphasis on combining physical device efficacy with the benefits of AI-supported patient monitoring and telehealth consultations underlines its commitment to delivering impactful, patient-centric healthcare solutions.

Rhea-AI Summary
Allurion Technologies, Inc. has announced that Somerset NHS Foundation Trust is the first NHS trust in the UK to introduce the Allurion Gastric Balloon, a swallowable gastric balloon that requires no surgery, endoscopy, or anesthesia. The balloon helps patients lose 10-15% of their body weight in 4 months and is proven to be safe and effective. The Allurion Program is particularly effective for patients with a higher BMI and is expected to save the NHS significant time and money compared to bariatric surgery. The program also includes an AI-powered behavior change program and 1-1 support from doctors and nutritionists. The partnership between Allurion and the NHS addresses the need for scalable, evidence-based weight solutions in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the introduction of the Allurion Gastric Balloon by the Somerset NHS Foundation Trust, marking the first time a non-private sector organization in the world has introduced this innovative swallowable gastric balloon. The balloon, which is filled and remains in the stomach for approximately 4 months, has been proven to help patients lose an average of 10-15% of their body weight. The treatment is expected to save the NHS significant time and money as it is substantially less expensive than bariatric surgery. The partnership between Allurion and the NHS aims to provide a weight loss solution that does not tap into surgical or endoscopic resources that are already overbooked and constrained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (ALUR) has expanded its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo and Transform, two of Europe’s largest aesthetic and weight loss groups. The VCS has shown positive results in increasing patient accountability, practice efficiency, and patient engagement, with clinics reporting an average 11% additional weight loss and over 16% additional patients reaching their goals. This expansion underscores the growing opportunities for the digital platform since launching Coach Iris—Allurion’s 24/7 AI-powered weight loss coach. The VCS now provides 24/7 coaching and guidance to patients across multiple modalities of care, including anti-obesity medications, devices, and bariatric surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.72%
Tags
partnership
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the publication of a study demonstrating significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. Weight loss was 13.7% at 4 months, with resolution of type 2 diabetes, hypertension, and obstructive sleep apnea observed in 55.5%, 58.8%, and 57.8%, respectively. Results improved with the addition of oral GLP-1 agonist semaglutide, with weight loss improving to 17.6% and co-morbidity resolution improving to 64.7%, 64.3%, and 72%, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announces substantial procedure growth in 2023 driven by best-in-class efficacy of balloon program. The company also prioritizes key investments in strategic markets and digital innovations ahead of FDA milestones. Preliminary unaudited results for the fourth quarter and full year 2023 show a 30% procedure volume growth, reflecting significant demand for the Allurion Program. CEO Dr. Shantanu Gaur emphasizes the company's focus on reducing cost structure, optimizing capital structure, and accelerating the path to profitability in the 2024 outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced the results of research on the impact of the changing weight-loss market on the Allurion Program. The research included 172 healthcare professionals and 1663 patients across 64 countries. Almost 90% of HCPs believed the Allurion Program was an ideal first-line treatment to achieve >10% body weight loss in a fast and sustainable way. The global market for anti-obesity medications, specifically GLP-1s, is expected to reach $100 billion by 2030. The survey results highlighted a belief among HCPs that the introduction of anti-obesity medications like GLP-1s had a positive impact on raising awareness of, and generating interest in, other medical weight-loss treatment options, including the Allurion Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE:ALUR) announces expanded commercial agreement with Weight Doctors and hiring of Brian Conyer to lead commercialization of digital assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
partnership
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) announced its financial results for Q3 2023, reporting a 40% sequential revenue growth and completion of business combination with Compute Health. The company also launched Coach Iris, an AI-powered weight loss coach, and completed enrollment in the AUDACITY trial for Allurion Balloon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
-
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) will be participating in the Jefferies London Healthcare Conference on November 14-16, 2023. The company's CEO and CFO will present on November 15 at 9:30 a.m. GMT and will be available for investor meetings. A live webcast of the event will be available on the Allurion website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
conferences
Rhea-AI Summary
Allurion Technologies, Inc. (NYSE: ALUR) will report financial results for Q3 2023 on November 13, 2023. A conference call will be held at 8:30 AM ET on the same day to discuss financial results and provide a business update. Access details for the call and webcast are available on Allurion's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
conferences earnings

FAQ

What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?

The current stock price of ALLURION TECHNOLOGIES (ALUR) is $3.2 as of March 28, 2025.

What is the market cap of ALLURION TECHNOLOGIES (ALUR)?

The market cap of ALLURION TECHNOLOGIES (ALUR) is approximately 19.5M.

What is the core focus of Allurion Technologies Inc?

Allurion Technologies Inc specializes in a non-invasive weight loss platform that combines a swallowable intragastric balloon with a suite of digital health tools, including AI-powered remote monitoring and telehealth services.

How does the Allurion Program work?

The Allurion Program utilizes a capsule-based intragastric balloon that is swallowed and deployed without surgery, coupled with digital support for patient monitoring and behavioral guidance, all under healthcare provider supervision.

What distinguishes Allurion's weight loss solution from traditional methods?

Unlike traditional surgical options, Allurion's solution is procedure-less and non-invasive, minimizing patient risk and recovery time while leveraging integrated digital tools for continuous care and support.

Who can benefit from Allurion's weight loss platform?

The platform is designed for overweight individuals seeking a medically supervised, non-surgical weight loss solution, and is recommended by healthcare professionals for safe and effective weight management.

How is advanced technology integrated into Allurion's services?

Allurion integrates AI-powered remote monitoring, secure messaging, and telehealth consultations into its weight loss platform, ensuring real-time patient support and personalized behavioral interventions.

How does Allurion maintain trust and safety in its offerings?

The company emphasizes robust clinical protocols, rigorous quality control, and continuous technological enhancements, ensuring that both patients and healthcare providers can trust the efficacy and safety of its non-invasive weight loss solution.
ALLURION TECHNOLOGIES INC

NYSE:ALUR

ALUR Rankings

ALUR Stock Data

19.50M
5.40M
13.85%
22.25%
2.11%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NATICK